tiprankstipranks
Amgen (GB:0R0T)
LSE:0R0T

Amgen (0R0T) Share Price & Analysis

2 Followers

0R0T Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$205.43 - $324.19
Previous Close$310.75
Volume2.52K
Average Volume (3M)16.06K
Market Cap
$167.62B
Enterprise Value$221.93B
Total Cash (Recent Filing)$9.71B
Total Debt (Recent Filing)$64.02B
Price to Earnings (P/E)44.4
Beta0.50
Jul 30, 2024
Dividend Yield2.77%
Share Statistics
EPS (TTM)6.99
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume16,056
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit11.24
Enterprise Value/Ebitda18.23
Forecast
Price Target Upside3.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20

Bulls Say, Bears Say

Bulls Say
Drug ApprovalFDA approved tarla early for 2L+ small cell lung cancer which is an incremental positive.
Market PotentialAnalyst expects Amgen can meaningfully penetrate the SCLC market following tarlatamab's approval with significant sales potential.
Safety ProfileTarlatamab has limited CRS to Grade 2 or lower events, which may increase physician comfort with its safety profile.
Bears Say
Company ReputationThe company has a history of overpromising and underdelivering.
Drug Efficacy And SafetyPh1 data raised questions around Maritide's tolerability, showing high adverse event rates, which is higher than existing incretins.
Financial PerformanceProduct sales came in about $100MM light, driven by weak sales in several key products.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

1.08%21.40%43.24%34.28%
43.24% Other Institutional Investors
34.28% Public Companies and
Individual Investors

0R0T FAQ

What was Amgen’s price range in the past 12 months?
Amgen lowest share price was $205.43 and its highest was $324.19 in the past 12 months.
    What is Amgen’s market cap?
    Currently, no data Available
    When is Amgen’s upcoming earnings report date?
    Amgen’s upcoming earnings report date is Jul 30, 2024 which is in 71 days.
      How were Amgen’s earnings last quarter?
      Amgen released its earnings results on May 02, 2024. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.879 by $0.081.
        Is Amgen overvalued?
        According to Wall Street analysts Amgen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Amgen pay dividends?
          Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.77%. See more information on Amgen dividends here
            What is Amgen’s EPS estimate?
            Amgen’s EPS estimate is $4.97.
              How many shares outstanding does Amgen have?
              Amgen has 536,434,700 shares outstanding.
                What happened to Amgen’s price movement after its last earnings report?
                Amgen reported an EPS of $3.96 in its last earnings report, beating expectations of $3.879. Following the earnings report the stock price went up 10.479%.
                  Which hedge fund is a major shareholder of Amgen?
                  Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
                    ---

                    Company Description

                    Amgen

                    Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
                    ---

                    0R0T Company Deck

                    ---

                    0R0T Earnings Call

                    Q1 2024
                    0:00 / 0:00
                    ---

                    0R0T Revenue Breakdown

                    14.36%14.36%13.11%7.76%7.49%57.27%
                    14.36% Prolia
                    13.11% Enbrel
                    7.76% Otezla
                    7.49% XGEVA
                    57.27% Other
                    tipranks
                    ---

                    0R0T Stock 12 Month Forecast

                    Average Price Target

                    $322.75
                    ▲(3.86% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"208":"$208","381":"$381","251.25":"$251.3","294.5":"$294.5","337.75":"$337.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":322.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$322.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$215.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[208,251.25,294.5,337.75,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.537,309.4187692307692,315.30053846153845,321.1823076923077,327.0640769230769,332.94584615384616,338.82761538461534,344.7093846153846,350.5911538461538,356.47292307692305,362.3546923076923,368.2364615384615,374.11823076923076,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.537,305.0149230769231,306.49284615384613,307.97076923076924,309.4486923076923,310.9266153846154,312.40453846153844,313.88246153846154,315.3603846153846,316.8383076923077,318.31623076923074,319.79415384615385,321.27207692307695,{"y":322.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,303.537,296.72646153846154,289.91592307692304,283.1053846153846,276.29484615384615,269.48430769230765,262.6737692307692,255.86323076923077,249.0526923076923,242.24215384615383,235.43161538461538,228.6210769230769,221.81053846153844,{"y":215,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":217.83,"date":1684454400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":209.592,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":212.257,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":237.699,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":250.884,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":260.412,"date":1696550400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":263.832,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":265.467,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.234,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":316.689,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.718,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.791,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.537,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Amgen
                    Biogen
                    Gilead Sciences
                    Johnson & Johnson

                    Best Analysts Covering 0R0T

                    1 Year
                    Yaron WerberTD Cowen
                    1 Year Success Rate
                    24/28 ratings generated profit
                    86%
                    1 Year Average Return
                    +16.77%
                    reiterated a buy rating 17 days ago
                    Copying Yaron Werber's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +16.77% per trade.
                    Popular Stocks
                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis